



8419

0300

COPY OF PAPERS
ORIGINALLY FILED

PATENT

Hight
AP
6-502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Panchal, et al.
SERIAL NO : 109/022,127
FILED : October 30, 2001
TITLE : HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDES AND
METHODS OF USE FOR SAME

Conf. No. : 1718
Docket No. : P03357US2

TRANSMITTAL LETTER

To the Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply With Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, pursuant to 37 CFR
1.821(e), applicant respectfully submits the following remarks.

A paper copy of the sequence listing accompanied the above-identified continuation
application filed October 30, 2001, along with a request for the transfer of the computer readable
copy of the sequences from the parent application, serial number 09/229,212. A copy of the
above-mentioned documents are enclosed for the Examiner's review. It is submitted that this
complies with the sequence requirements.


It is believed no fees are required at this time. However if any additional fees are needed,
please charge Deposit Account No. 26-0084.

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this document and the documents referred to as enclosed therein are being deposited
with the United States Postal Service as First Class mail in an envelope addressed to: Assistant Commissioner for
Patents, Washington, D.C. 20231, on this 12 day of February, 2002.

Heidi S. Nebel

Respectfully submitted,



Heidi S. Nebel, Reg. No. 37,719
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

Attorneys of Record

- pw -



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/022,127	10/30/2001	Rekha G. Panchal	P03357US2

22885
MCKEE, VOORHEES & SEASE, P.L.C.
801 GRAND AVENUE
SUITE 3200
DES MOINES, IA 50309-2721

CONFIRMATION NO. 1718

FORMALITIES LETTER



OC000000007332741

Date Mailed: 01/18/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT Panchal, et al.
Serial No.: CONTINUATION APPLICATION OF 09/229,212
Filed: October 30, 2001
Title: HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDES AND
METHODS OF USE FOR SAME

Receipt is hereby acknowledged of the accompanying:

- Utility Patent Application Transmittal
- Fee Transmittal
- Patent Application (54 pages)
- Oath/Declaration (previously filed in parent application) 6 pages
- Drawings (10 pages)
- Application Data Sheet (2 pages)
- Statement Under 37 CFR 3.73(b) with copy of recorded assignment
- Information Disclosure Statement and PTPO/SB08A and 08B
- Request to Transfer Sequence Listing From Parent Application


On October 23, 2001 the above described documents were mailed to the
Assistant Commissioner for Patents, Washington, D.C. 20231

P03357US2


HGTRI 1078-154

pw/HSN

J1011 U.S. PTO
10/022127



EKS

COPY OF PAPERS
ORIGINALLY FILEDPlease type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	P03357US2
First Inventor	PANCHAL, Rekha G.
Title	HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDE
Express Mail Label No.	EL911005635US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 54]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 10]
5. Oath or Declaration [Total Pages 6]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ paper
 - c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☒ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)of prior application No.: 09, 229,212

Prior application information:

Examiner J. EppsGroup Art Unit: 1635

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label22885or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

515-288-3667

Fax

515-288-1338

Name (Print/Type)

Reidi S. Nebel

Registration No. (Attorney/Agent)

37,719

Signature

Date

October 30, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.